Dr. Shruthi Harish Bindiganavile, MD

Dr. Harish Bindiganavile practices at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.

Dr. Harish Bindiganavile's NPI, 1225522253, was assigned on June 22, 2018. Dr. Harish Bindiganavile holds Pennsylvania license MD481651.

Dr. Harish Bindiganavile's primary practice is Thomas Jefferson University Hospital, at 111 S 11th St, Philadelphia, PA 19107 in Philadelphia County. The practice phone is (215) 955-4038.

Dr. Harish Bindiganavile's primary practice is Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Dr. Harish Bindiganavile is also affiliated with Hospital of the University of Pennsylvania. Dmand AI also links Dr. Harish Bindiganavile to 5 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Harish Bindiganavile practices, 6 sites in all. Vendor and product names are available with a free account.

Neuro-ophthalmology is Dr. Harish Bindiganavile's primary specialty in the NPI Registry, under taxonomy code 207WX0109X. Dr. Harish Bindiganavile is licensed in Pennsylvania.

CMS data shows 1,142 Medicare services from Dr. Harish Bindiganavile across 6 procedure codes in 2024, for 314 Medicare patients. Medicare paid $82,738 for them. Every service was in an office.

CMS counts 314 Medicare patients who saw Dr. Harish Bindiganavile in 2024. The largest group is 65 to 74, with 120 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Harish Bindiganavile's median patient age at 65, with 62% women.

In 2024, Dr. Harish Bindiganavile wrote 214 Medicare Part D claims for 76 patients. 98% of them were for generic drugs. CMS names the drug for 172 of them, across 5 drugs with 11 or more claims each, at $2,452 in total drug cost. In 2023, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Harish Bindiganavile for performance year 2024, reported as part of a group. Dr. Harish Bindiganavile accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Harish Bindiganavile as offering telehealth.

Dmand AI links 14 papers to Dr. Harish Bindiganavile, published from 2020 to 2022. 2021 was the busiest year, with 3. The most frequent topics are Visual Acuity, Visual Fields and Magnetic Resonance Imaging. Dr. Harish Bindiganavile has published most often in J Neuroophthalmol. Dr. Harish Bindiganavile's most frequent co-authors are Nita Bhat, MD, Andrew G. Lee, MD and Robert A. Avery, DO.

CMS Open Payments shows 26 general payments to Dr. Harish Bindiganavile from 7 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. UCB, Inc. paid the most, $311.